# CORRECTION

# Correction to: Cross-sectional study of medical advertisements in a national general medical journal: evidence, cost, and safe use of advertised versus comparative drugs

Kim Boesen<sup>1,2\*</sup>, Anders Lykkemark Simonsen<sup>1</sup>, Karsten Juhl Jørgensen<sup>1,3,4</sup> and Peter C. Gøtzsche<sup>5</sup>

## Correction to: Res Integr Peer Rev 6, 8 (2021) https://doi.org/10.1186/s41073-021-00111-9

Following publication of the original article [1], the authors noted that an incorrect file for Supplementary file 1 had been published. The corrected version of Supplementary file 1 is attached to this Correction and it has also been updated in the original article, accordingly.

### Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s41073-021-00114-6.

Additional file 1.

#### Author details

<sup>1</sup>Nordic Cochrane Centre, Rigshospitalet Dept. 7811, 2100 Copenhagen, Denmark. <sup>2</sup>Current address: Meta Research Innovation Center Berlin (METR IC-B), Berlin Institute of Health, Charité Universitätsmedizin, QUEST Center for Transforming Biomedical Research, Berlin, Germany. <sup>3</sup>Centre for Evidence-Based Medicine (CEBMO) and Cochrane Denmark, Dept. Clinical Research, University of Southern Denmark, Odense, Denmark. <sup>4</sup>Open Patient data Exploratory Network (OPEN), Odense University Hospital, Odense, Denmark. <sup>5</sup>Institute for Scientific Freedom, 2970 Copenhagen, Denmark.

The original article can be found online at https://doi.org/10.1186/s41073-021-00111-9

\* Correspondence: kim.boesen@charite.de

<sup>1</sup>Nordic Cochrane Centre, Rigshospitalet Dept. 7811, 2100 Copenhagen, Denmark

<sup>2</sup>Current address: Meta Research Innovation Center Berlin (METR IC-B), Berlin Institute of Health, Charité Universitätsmedizin, QUEST Center for Transforming Biomedical Research, Berlin, Germany

Published online: 11 June 2021

#### Reference

Boesen, et al. Cross-sectional study of medical advertisements in a national 1. general medical journal: evidence, cost, and safe use of advertised versus comparative drugs. Res Integr Peer Rev. 2021;6:8. https://doi.org/10.1186/s41 073-021-00111-9.

© The Author(s), 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License. which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.





**Open Access**